000144875 001__ 144875
000144875 005__ 20240229123021.0
000144875 0247_ $$2doi$$a10.1002/ijc.32610
000144875 0247_ $$2pmid$$apmid:31376284
000144875 0247_ $$2ISSN$$a0020-7136
000144875 0247_ $$2ISSN$$a1097-0215
000144875 0247_ $$2altmetric$$aaltmetric:64713187
000144875 037__ $$aDKFZ-2019-02299
000144875 041__ $$aeng
000144875 082__ $$a610
000144875 1001_ $$0P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aHolleczek, Bernd$$b0$$eFirst author
000144875 245__ $$aHelicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study.
000144875 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000144875 3367_ $$2DRIVER$$aarticle
000144875 3367_ $$2DataCite$$aOutput Types/Journal article
000144875 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601378881_26602
000144875 3367_ $$2BibTeX$$aARTICLE
000144875 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144875 3367_ $$00$$2EndNote$$aJournal Article
000144875 500__ $$a2020 May 15;146(10):2773-2783#EA:C070#LA:C070#
000144875 520__ $$aHelicobacter pylori (H. pylori) infection is considered as principal cause of gastric cancer. It is further associated with a reduced risk of esophageal adenocarcinomas. In a large prospective population-based cohort study including 9,949 subjects with average observation time of 13.8 years, we assessed the risk of invasive gastric and esophageal cancer according to H. pylori infection and presence of chronic atrophic gastritis (CAG). Incidence rates and hazard ratios (HR) derived by Cox proportional hazards models and adjusted for relevant confounders were derived by seroprevalence of H. pylori and cytotoxin-associated gene A (CagA) antibodies and presence of CAG based on serological markers at baseline, respectively. During follow-up, 30 cases of noncardia gastric cancer and 33 cases of esophageal cancer were observed. Infection by H. pylori without and with expression of CagA was associated with a 5.2-fold (95% confidence interval 1.00-27.1) and an 18.2-fold (4.3-77.4) increase of noncardia gastric cancer incidence. A 0.65-fold decreased risk of esophageal adenocarcinomas (HR 0.35, 0.12-0.97) was observed among H. pylori-infected individuals. In participants infected with CagA expressed H. pylori, the presence of mild/moderate and severe CAG was associated with a 6.4-fold (1.3-31.0) and an 11.8-fold (3.1-45.4) increase of gastric cancer incidence, respectively. The results of this prospective population-based cohort study may contribute relevant evidence to the ongoing research of H. pylori-related cancers. The results may furthermore enhance the empirical basis for risk stratification among H. pylori-infected people and for recommendations regarding H. pylori screening and treatment among older adults in a Western population.
000144875 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144875 588__ $$aDataset connected to CrossRef, PubMed,
000144875 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b1$$udkfz
000144875 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$eLast author
000144875 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32610$$gp. ijc.32610$$n10$$p2773-2783$$tInternational journal of cancer$$v146$$x1097-0215$$y2020
000144875 909CO $$ooai:inrepo02.dkfz.de:144875$$pVDB
000144875 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144875 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144875 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144875 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144875 9141_ $$y2020
000144875 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144875 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144875 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144875 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144875 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000144875 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144875 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144875 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144875 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144875 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144875 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144875 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000144875 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144875 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144875 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144875 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000144875 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000144875 980__ $$ajournal
000144875 980__ $$aVDB
000144875 980__ $$aI:(DE-He78)C070-20160331
000144875 980__ $$aI:(DE-He78)C120-20160331
000144875 980__ $$aI:(DE-He78)HD01-20160331
000144875 980__ $$aUNRESTRICTED